Evaluation of interleukin-10 and transforming growth factor-Ý in human hepatocellular carcinoma cell line subjected to "sorafenib-taurine" therapeutic model / Ahmed Motawa Eisa Elhouseini ; Supervised Ahmed Mohamed Fathi Afifi , Reda Hasan Tabashy , Mohamed Ahmed Khalil
Material type:
- تقييم " الانترلوكين-10" و" عامل النمو التحويلي - بيتا" في خلايا الكبد السرطاني الخبيث للأنسان بعد التعرض للنموذج العلاجي " سورافينيب - تاورين [Added title page title]
- Issued also as CD
Item type | Current library | Home library | Call number | Copy number | Status | Barcode | |
---|---|---|---|---|---|---|---|
![]() |
قاعة الرسائل الجامعية - الدور الاول | المكتبة المركزبة الجديدة - جامعة القاهرة | Cai01.12.21.M.Sc.2018.Ah.E (Browse shelf(Opens below)) | Not for loan | 01010110077430000 | ||
![]() |
مخـــزن الرســائل الجـــامعية - البدروم | المكتبة المركزبة الجديدة - جامعة القاهرة | Cai01.12.21.M.Sc.2018.Ah.E (Browse shelf(Opens below)) | 77430.CD | Not for loan | 01020110077430000 |
Thesis (M.Sc.) - Cairo University - Faculty of Science - Department of Zoology
Sorafenib (Sor) is a multi-kinase inhibitor, it is recommended for the treatment of advanced hepatocellular carcinoma (HCC). However, Sor has severe and marked side effects. Taurine (Tau) has been shown to enhance the therapeutic effects of cancer chemotherapy and also to enhance the function of leukocytes. Aim of the study: The present study aimed to investigate the immunological aspects of Sor, Taurine as well as after combination on human hepatocytes. Materials and Methods: HepG2 cell line was cultured to determine IC50 using SRB assay. The levels of TGF-Ý and IL-10 released in culture media of the cells were determined by ELISA
Issued also as CD
There are no comments on this title.